Let’s take life sciences as an example. No-one would suggest for a moment that we need to take risks with people’s health, and we need to know that medicines are safe before they are administered to trusting patients.
The U.S. Food and Drug Administration today approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Ubrelvy is not indicated for the preventive treatment of migraine. It is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine.
Ubrelvy is an oral calcitonin gene-related peptide receptor antagonist now approved for the treatment of acute migraines, an FDA press announcement reported. The grant was awarded to Allergan USA, Inc. In clinical trials conducted on over 1,400, the medication was found to be effective in the quick treatment of migraine.
For those who suffer from insomnia, the answer is not simple. Of the few medications on the market, many cause a slew of unpleasant and sometimes dangerous side effects. However, recently the FDA approved a new insomnia medication that may serve as an alternative. The drug, named lemborexant (Dayvigo), was found to particularly help seniors stay asleep.
Eli Lilly and Company (NYSE:LLY) offers an attractive opportunity for shareholders in 2020. The more than 140-year-old drug company has a few compelling metrics that demonstrate significant value for investors, including a strong return on equity (ROE), a modest dividend payout ratio, and continued profitability when compared with peers including GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE).
Lannett Company (NYSE:LCI), a small-cap drug manufacturer, received FDA approval for Numbrino, the first branded drug in the company's 78-year history. The nasal spray will be marketed to doctors as a local anesthetic for minor surgeries around the nasal cavities of patients, but will not be available in retail pharmacies.
And the costs of the inefficient, error-prone process that is drug discovery are not only high but increasing. Where Moore’s Law illustrates the cheapening and "easy access" of digitization in many technology fields, the pharmaceutical industry has the cleverly named Eroom’s Law ("Moore" spelled backward), described by Jack Scannell and team in 2012, that shows that the number of new drugs approved by the FDA per billion U.S. dollars (inflation-adjusted) spent on R&D has halved roughly every 9 years.
OnRamp.Bio's flagship product, ROSALIND™, enables researchers, drug developers and bench scientists to analyze raw genomics data by providing a transformative experience through point-and-click experiment set up, interactive data visualization and interpretation. This new approach increases productivity by freeing up time for the bioinformatician to focus on more challenging workloads while making bioinformatic analysis more accessible for the scientist to do more discovery with their data.
Cofactor is a large, structured listing of people, places, and things. Here you can find the description of each topic.